(GKOS) Glaukos - Ratings and Ratios

Glaukos Corporation (NYSE:GKOS) is a leader in ophthalmic medical technology and pharmaceuticals, specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases. The companys flagship products include the iStent and iStent inject W micro-bypass stents, which address mild-to-moderate open-angle glaucoma by enhancing aqueous humor outflow. Its portfolio also features the iStent infinite, designed for advanced glaucoma cases, and the iDose TR, an intracameral therapy for reducing intraocular pressure. Additional offerings include surgical tools like the iAccess precision blade and the iPRIME viscoelastic delivery system. Glaukos is also advancing pipeline innovations such as the iLink device for keratoconus treatment, the ILution platform for transdermal drug delivery, and the retinal XR platform targeting posterior segment retinal diseases. The company distributes its products globally through direct sales teams, subsidiaries, and distributors, serving ambulatory surgery centers, hospitals, and private physician practices. Headquartered in Aliso Viejo, California, Glaukos Corporation was founded in 1998 and has established itself as a pioneer in minimally invasive glaucoma therapies.

3-Month Forecast: Based on technical and fundamental analysis, Glaukos Corp (GKOS) is expected to experience price consolidation between $90 and $100 in the near term. The stock is currently trading below its 20-day and 50-day SMAs, signaling bearish momentum. However, the ATR of 5.62 suggests moderate volatility, with potential downside limited by the SMA 200 at $128.50. Fundamental analysis highlights a high P/S ratio of 13.44, indicating strong revenue growth expectations, but the negative RoE of -19.09% raises concerns about profitability. Investors should monitor the companys ability to balance growth with operational efficiency in the coming months.